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ABSTRACT
Terminal fucosylated motifs of glycoproteins and glycolipid chains are often 
altered in cancer cells. We investigated the link between fucosylation changes and 
critical steps in cancer progression: epithelial-to-mesenchymal transition (EMT) and 
lymph node metastasis.
Using mammary cell lines, we demonstrate that during EMT, expression of some 
fucosylated antigens (e.g.: Lewis Y) is decreased as a result of repression of the 
fucosyltransferase genes FUT1 and FUT3. Moreover, we identify the fucose-binding 
bacterial lectin BC2L-C-Nt as a specific probe for the epithelial state. 
Prolectin (CLEC17A), a human lectin found on lymph node B cells, shares ligand 
specificities with BC2L-C-Nt. It binds preferentially to epithelial rather than to 
mesenchymal cells, and microfluidic experiments showed that prolectin behaves as 
a cell adhesion molecule for epithelial cells. Comparison of paired primary tumors/
lymph node metastases revealed an increase of prolectin staining in metastasis and 
high FUT1 and FUT3 mRNA expression was associated with poor prognosis. Our data 
suggest that tumor cells invading the lymph nodes and expressing fucosylated motifs 
associated with the epithelial state could use prolectin as a colonization factor.
INTRODUCTION
Alterations of glycosylation are a hallmark of 
cancer. In particular, N- or O-glycans of proteins as well 
as glycolipids produced by cancer cells often carry an 
increased number of fucosylated motifs of the Lewis blood 
groups family [1, 2]. Elevated levels of Lewis Y (Ley), 
Sialyl-Lewis A (SLea) or Sialyl-Lex (SLex) have been found 
in numerous types of carcinomas including colon or breast. 
Expression of such motifs has been shown to be associated 
with disturbance of the cell adhesion properties, increase 
in the migration capacity and invasion of ectopic tissues 
[3–5]. Although sialylated Lewis antigens have clearly 
been demonstrated to favor cancer cells extravasation 
through their interaction with selectins expressed on 
leukocytes or endothelial cells, functional consequences of 
neutral fucosylated antigens overexpression have remained 
elusive. Before entering the circulation, carcinoma cells 
go through a reversible cellular process called epithelial-
to-mesenchymal transition (EMT). EMT occurs during 
normal development and is also a hallmark of cancers. 
It consists in the loss of cell-cell contact and acquisition 
of mobility and invasiveness properties and has been 
involved in metastasis. EMT is characterized by a decrease 
in the expression of adhesion-related proteins (typically 
E-Cadherin) and increased expression level of various 
factors such as the cytoskeletal protein vimentin. The 
genetic reprogramming accompanying EMT is regulated 
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by various transcription factors, belonging to 3 main 
families (Snail, Zeb and Twist) as well as by miRNAs, 
especially from the miR200 family, and can be triggered 
by cytokines such as TGF-β. Generation of cancer stem 
cells (CSC) has also been associated with EMT (reviewed 
in [6]). It is generally assumed that in order to colonize 
foreign tissue and establish metastasis, cells have to 
go through the reverse mechanism, mesenchymal-to-
epithelial transition (MET), however this process has not 
received as much attention as EMT.
As an alternative to the use of antibodies for the 
detection of abnormal glycosylations in cancer patients, 
proteins with carbohydrate-binding properties called 
lectins have been investigated. Although they were first 
identified in plants, lectins are present in all kinds of 
organisms from bacteria to humans. They are grouped 
in families according to their structural characteristics, 
chemical properties and ligand specificities [7]. Several 
lectins have been found to have relevance for cancer 
prognosis, including a lectin of the edible snail (Helix 
pomatia) and a lectin from the plant Maclura pomifera. 
Binding of those two lectins correlates with bad prognosis 
for breast and colon carcinomas [4, 8]. We recently 
identified the fungal lectin from Psathyrella velutina as a 
marker of truncated N-glycans present on lung cancer cells 
[9]. However use of lectins in the clinic has been limited 
until now, partly because of the difficulties associated with 
reliable production of lectins from plants or animals.
While lectins from plants, mushrooms or 
invertebrates have low affinity for human glycans, lectins 
from opportunistic bacteria, that have evolved to use 
human glycans as targets, could present stronger affinity 
and be used as specific markers. In the recent years, the 
α-galactose (Gal) specific LecA from Pseudomonas 
aeruginosa, the α-mannose (Man) specific Bc2L-A from 
Burkholderia cenocepacia and the α-fucose (Fuc) specific 
RSL from Ralstonia solanacearum were produced in 
recombinant form and described [10–12]. Of special 
interest, the BC2L-C-Nt lectin from B. cenocepacia has 
been successfully produced in a recombinant manner. It 
folds in a trimeric TNF-α-like structure and binds to α2-
fucosylated blood group antigens such as H type 1/3 or 
Ley [13, 14]. 
In this study we investigated the evolution and 
possible roles of fucosylated antigens expression during 
cancer progression. We used a panel of antibodies and 
lectins targeting Lewis antigens and found an association 
between expression of these antigens and the epithelial 
state, expression being lost in the mesenchymal state. 
We show that BC2L-C-Nt is a good tool to monitor these 
changes. 
Since some mammalian lectins, belonging to the 
calcium-dependant family (C-type lectins), are able to 
bind Lewis fucosylated antigens, we considered the 
possibility that endogenous lectins could play a role in 
tissue colonization via interaction with tumor cells after they 
have engaged in MET. Indeed, C-type lectins play a role 
in processes such as cell-adhesion, leucocyte extravasation 
and pathogen recognition [2, 15]. Our observation of a link 
between the epithelial state and expression of fucosylated 
glycans revealed using the BC2L-C-Nt bacterial lectin 
prompted us to look for potential endogenous lectins with 
similar glycan specificity. One intriguing member of this 
family is prolectin (encoded by the CLEC17A gene), which 
seems to be expressed mainly in dividing B cells found 
in the germinal centers of secondary lymphoid organs. 
Prolectin is a type II membrane protein with an extracellular 
carbohydrate-recognition domain (CRD) closely resembling 
the CRD of the well-characterized dendritic cell lectin DC-
SIGN. However, the exact function of prolectin remains 
unknown [16]. Here we show that Prolectin can serve as 
a cell adhesion molecule for fucosylated epithelial cancer 
cells. We suggest a model presenting a possible role of 
prolectin in implantation of metastases in lymph nodes. 
RESULTS
Epithelial cells express more fucosylated antigens 
than mesenchymal cells
EMT is characterized by a profound reprogramming 
of cellular gene expression. We thus sought to 
identify differences in histo-blood group antigens 
(HBGAs) displayed on the membranes of epithelial 
and mesenchymal cells (See Figure S1 for a diagram 
of HBGA synthesis pathways). We worked on breast 
cancer cell lines for which the EMT status has been well 
described. In addition, we used two EMT models based 
on the immortalized epithelial breast cell line MCF10A, 
from which mesenchymal counterparts had been derived 
by transfection with EMT-inducing factors, respectively 
the constitutively active oncogene Kras(v12) and the 
transcription factor SNAIL (SNAI1 gene). The control 
cell lines transfected with empty vectors and selected 
in parallel of MCF10A-KRAS(v12) and MCF10A-
SNAIL are referred to thereafter as MCF10A-LXSN and 
MCF10A-PuroR respectively. We looked at the expression 
of several cancer-associated fucosylated antigens using 
flow cytometry and appropriate mouse mAbs (Figure 1A 
and 1B). All epithelial breast cell lines were found to 
express Ley as well as Lex and H type 3 antigens, except 
the non-cancerous cell lines MCF10A-LXSN/MCF10A-
PuroR that expressed only Ley. The slight difference in 
Ley expression profile between the two MCF10A control 
cell lines is probably due to clonal selection. Nonetheless, 
none of the neutral fucosylated antigens were detected on 
mesenchymal cell lines, including MCF10A-Kras(v12) 
and MCF10A-SNAIL. Some epithelial (MCF10A-LXSN, 
MCF10A-PuroR, ZR-75.1) as well as mesenchymal cell 
lines (BT-549, MDA-MB-231, MCF10A-KRAS(v12), 
MCF10A-SNAIL) were positive for SLex expression 
detected by the KM-93 antibody. However the HECA-452 
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Figure 1: Expression of fucosylated antigens by mammary cell lines. Breast cell lines from tumor origin (A) or derived from 
the immortalized MCF10A cell line (B) were subjected to flow cytometry using various antibodies directed against fucosylated histo-
blood groups antigens, followed by an anti-mouse-FITC secondary antibody. The horizontal axis represents mean fluorescence intensity 
(MFI) while cell count is indicated on the vertical axis. Structures of the glycan epitopes recognized by each antibody are shown below the 
antibody description.
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antibody that is more fucose dependent than the KM-93 
[17] only stained epithelial cell lines (ZR75.1, MCF10A-
LXSN and MCF10A-PuroR). SLea was poorly expressed 
if at all on the breast cell lines tested except for ZR75.1. 
BC2L-C-Nt preferentially binds to epithelial 
breast cell lines
We then tested fucose-specific bacterial lectins: BC2L-
C-Nt from B. cenocepacia and the broadly fucose-specific 
RSL from R. solanacearum. As a comparison, we also tested the 
well-characterized α2-fucose-specific plant lectin Ulex euro­
peaus agglutinin­I (UEA-I). Lectins used are listed in Table S1
We found that the BC2L-C-Nt staining was 
clearly higher on cell lines characterized as epithelial 
as compared to those characterized as mesenchymal 
(Figure 2). Interestingly, other fucose-specific lectins such 
as UEA-I and RSL did not distinguish between the two 
phenotypes as clearly as BC2L-C-Nt (Figure S2A). In 
order to determine if lectins with other types of specificity 
could present a similar or complementary binding profiles 
compared to BC2L-C-Nt, we tested BC2L-A, and LecA, 
specific for mannose and galactose respectively and 
neither of these lectins showed a clear distinction between 
epithelial and mesenchymal cells (Figure S2B). 
Epithelial cells express higher levels of FUT1 and 
FUT3 than mesenchymal cells
In order to confirm the epithelial preference of 
BC2L-C-Nt, we treated MCF10A cells with TGF-ß, 
which was able to induce a partial EMT as shown by: (1) 
morphological change (Figure 3A), (2) vimentin induction 
as shown by immunofluorescence (Figure 3B) and flow 
cytometry (Figure S3) and (3C) a reduction of E-cadherin 
mRNA expression and an increase of SNAIL and SLUG 
mRNA expression  (See Figure 3C). We performed FACS 
analysis with anti-Ley and anti-SLex on TGF-ß treated cell. 
Although we could not observe a decrease in the 12-4LE 
staining, KM-93 and HECA-45 labeling were reduced 
by respectively 40 and 70% (Figure S3). We also found 
a small but significant reduction in BC2L-C-Nt staining 
in cells treated with TGF-ß (Figure 3D). Reversion to the 
epithelial phenotype (MET) could be partially achieved 
by withdrawing TGF-β (as shown by a reduction of 
vimentin expression as well as by increase of E-Cadherin 
and decrease of SNAIL and SLUG mRNAs levels, 
See Figure 3B and Figure 3C) and this was accompanied 
by an increase in BC2L-C-Nt staining (Figure 3D). We 
then investigated whether the difference in fucosylated 
antigen expression between epithelial and mesenchymal 
cell lines reflected a difference in fucosyltransferase gene 
expression. We first analyzed available transcriptomic data 
from a panel of 51 breast cancer cell lines [18]. Breast 
cell lines have been classified in categories called luminal, 
corresponding to the luminal A/B tumour histologic 
type and associated with a pronounced epithelial 
phenotype, Basal A, corresponding to the Basal tumor 
type and Basal B, characterized by a high expression of 
mesenchymal specific genes and CSC markers [19, 20]. 
In humans, 8 fucosyltransferases genes can contribute to 
the synthesis of fucosylated antigens: FUT1­7 and FUT9. 
FUT1 and FUT2 encode α 1–2-fucosyltransferases, 
whereas the others encode α 1–3/4-fucosyltransferases 
[21]. We observed that FUT5, 6, 7 and 9 were weakly 
or very weakly expressed in the breast cell lines. FUT1 
and FUT3 were significantly more expressed in luminal 
and Basal A cell lines than in the Basal B cell lines, 
whereas no significant difference was observed for FUT2 
and FUT4 (Figure S4). We therefore used the MCF10A 
model to check if there is a relationship between FUT1/
FUT3 expression and EMT. We performed qRT-PCR 
using FUT1­ and FUT3­specific probes on untreated 
or TGF-ß-treated MCF10A-LXSN cells, MCF10A-
Kras(v12) cells and MCF10A-PuroR/MCF10A-SNAIL 
cells. We observed that FUT3 expression was markedly 
reduced when EMT was induced by TGF-ß treatment. In 
addition, FUT3 expression was at least partially restored 
upon TGF-ß withdrawal. Moreover FUT3 was absent in 
cells overexpressing Kras(v12) or SNAIL. The FUT3 
gene expression pattern was strikingly similar to that of 
the CDH1 gene encoding E-cadherin, but in contrast with 
that of SNAI1 (SNAIL) and SNAI2 (SLUG) (Figure 3C 
and Figure S5). The association between FUT1 and EMT 
was less pronounced (Figure 3C), although its expression 
was suppressed by SNAIL overexpression (Figure S5). 
The above results prompted us to look at the promoter 
sequences of the FUT1 and FUT3 genes to see if there 
were binding motifs for the EMT inducing transcription 
factors. We found several E2-boxes (CAGGTG or 
CACCTG), which are classical SNAIL-binding motifs, 
similar to those that can be found in the E-cadherin 
promoter. Moreover, bipartite elements (C)AGGTG/
CACCT(G) are binding motifs for ZEB1/2, which are also 
EMT-inducing transcription factors [22, 23] (Figure S6A). 
Analysis of the transcriptome of the 51 breast cancer cell 
lines showed an inverse relationship between expression 
of FUT1/3 and of SNAI2 and ZEB1/2 (Figure S6B).
The above results from surface fucosylation staining 
and analysis of fucosyltransferase expression suggest that 
there is a relationship between surface expression of neutral 
α1, 2 and α1, 3/4 fucosylated glycans, and EMT/MET. 
The human C-type lectin prolectin has similar 
glycan specificity as BC2L-C-Nt and efficiently 
binds human cell lines and tumor tissues
The association between the epithelial state and 
fucosylated glycans that we demonstrated above could 
result in interaction with some endogenous lectin(s) in the 
metastatic microenvironment that could favor tumor cells 
implantation. We identified in databases the fucose-specific 
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lectin CLEC17A (prolectin) as a good candidate because it 
recognizes non-sialylated Lewis-type ligands and has the 
interesting property of being expressed mainly in secondary 
lymphoid organs, a very common site for tumor metastasis.
Prolectin is a type II transmembrane C-type 
lectin with an extracellular CRD and a cytoplasmic tail 
containing SH2 and SH3 signaling domains (Figure 4A). 
It has been shown to bind both poly-mannosylated ligands 
and neutral fucosylated ligands on the glycan microarray 
from the Consortium for Functional Glycomics [16].
The prolectin CRD was produced in bacterial cells, 
purified by gel filtration, biotinylated in vitro and used in 
Figure 2: The fucose binding lectin BC2L-C-Nt stains epithelial cells rather than mesenchymal cells. Breast cell lines 
were stained with biotinylated lectins BC2L-C-Nt followed by PE-conjugated streptavidin and analyzed by flow cytometry. Representative 
flow cytometry histograms as well as a histogram of the mean and SEM of Mean fluorescence intensities (MFI) for three independent 
experiments are presented.
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Figure 3: BC2L-C-Nt staining decreases following EMT induction in parallel with fucosyltransferase expression. 
MCF10A-LXSN cells were passaged in the presence of 10 ng/ml TGF-ß1 e-Bioscience to induce EMT (MCF10A+TGF-ß). The cells were 
then grown a further 4 days in the absence of TGF-ß to induce a MET (MCF10A-MET). (A) Morphological appearance of the cells. (B) 
MCF10A-LXSN epithelial cells were treated with either 0,5 µM A83-01 (MCF10A-LXSN) or 5 ng/ml TGF-ß1 R & D (MCF10A+TGF) 
during four days. TGF-ß was then withdrawn and cells were grown four more days in presence of 0,5 µM A83-01 (MCF10A-MET). 
Cells were analyzed by immunofluorescence using anti-E-cadherin and anti-Vimentin antibodies followed respectively by a Dylight 
488-conjugated and a Rhodamine-conjugated secondary antibody. Nuclei were stained with Hoechst. Pictures were taken with a Nikon 
confocal microscope at a x60 magnification (C) Total RNAs were extracted from the different cell lines and cDNAs were synthesized 
using oligo-dT and subjected to qPCR analysis with FUT1, FUT3 and GAPDH specific primers and probes. FUT1 and FUT3 expression 
levels are presented relative to GAPDH expression. The PCR on CDH1, SNAI1 and SNAI2 was performed using specific primers and 
SYBrGreen and results are presented relatively to ß­actin expression. Data shown are the mean and SEM of three independent experiments. 
(D) Binding of BC2L-C-Nt to cells analyzed by flow cytometry. The results are the means and SEM of the MFI of BC2L-C-Nt staining for 
four independent experiments including the three used in Figure 3C. Statistical significance has been assessed with 2-tailed paired t-tests 
between the indicated data sets.
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a tetrameric complex with streptavidin as described in 
Material and Methods. We then tested prolectin binding 
on a range of fucosylated ligands of the HBGA series. 
As lectin binding to carbohydrate is quite dependent on 
the underlying molecule, we used two different kinds of 
carriers: polyacrylamide beads (PAA) or human serum 
albumine (HSA).  
When we compared prolectin and BC2L-C-Nt 
binding on a range of neutral HBGAs, the two lectins 
showed quite similar but distinct binding profiles. In 
particular, Ley was one of the most efficiently recognized 
ligands for both of these lectins (Figure 4B; detailed 
formulas of the oligosaccharides used are given in 
Table S3). We went on to test prolectin binding to a panel 
of established tumor cell lines from various histological 
origins: breast, colon, ovary, prostate, which were all 
positive for Lex and Ley (Table S4). Prolectin was found 
to bind to all the tumor cell lines. As expected, this 
interaction is mediated by the sugar-binding site, as it was 
abolished by pre-incubation of the lectin with an excess of 
fucose monosaccharide (Figure 4C). 
We also tested prolectin binding on the MCF10A 
cell lines and found that the fluorescence level on 
MCF10A-LXSN and MCF10A-PuroR cells was markedly 
higher than on the Kras(v12)- and SNAIL-transfected 
counterparts, showing that, like BC2L-C-Nt (but to a 
lesser extent), prolectin displays a preference for epithelial 
cells (Figure 4D).
We tested prolectin binding to human tumor tissue 
sections from breast (N = 40), colon (N = 39), lung 
(N = 39) and uterine cervix (N = 50). Prolectin stained 
80–95% of the tumors (≥ 5% of positive cancer cells). 
The percentage of cancer cells stained was quite variable 
(between 5 and 100%) for breast and uterine tumors. Most 
lung and colon tumors presented ≥ 80% positive cells. 
We also noticed in some tumor samples a high number of 
infiltrating leucocytes that were strongly stained, although 
lymphoid tissues were mostly negative (Figure S7). Paired 
adjacent healthy tissue was generally much less stained 
that the corresponding tumor and the labeled structures 
were mostly the outer epithelial layers, preferentially on 
the apical side (Figure 4E). Again, this binding of prolectin 
was glycan dependent, as it was inhibited in the presence 
of EDTA, which chelates the Ca2+ of the CRD as well as 
in the presence of fucose (Figure 4E).
Prolectin can behave as an adhesion molecule for 
cells expressing fucosylated ligands
Since prolectin is a membrane C-type lectin, 
an interesting hypothesis was that it could mediate 
interactions with cells expressing the appropriate ligands, 
as selectins do with SLex expressing cells. We decided to 
investigate this possibility using the BioFlux microfluidic 
system. This system makes it possible to generate a 
tightly controlled shear flow pressure inside microfluidic 
channels, which can be coated with cells or proteins. As 
prolectin is expressed on B cells in the lymph nodes, the 
interaction with tumor cells is not expected to happen 
in the blood stream (in contrast to the interaction with 
selectins), however we thought that performing our 
experiments under a low shear flow (0,05–0.1 Dyn/cm2) 
would correspond to the situation of motile cells reaching 
lymphoid organ cells and would additionally give higher 
stringency for the study of cell-prolectin interaction than 
using static conditions.
We coated the microchannels with prolectin CRD/
streptavidin tetramers and injected Chinese hamster 
ovary (CHO) cells transfected with one or several 
glycosyltransferases so as to make them express various 
fucosylated ligands (H type 2, Lea, Leb; Figure S8). A 
few normal CHO cells bound to the prolectin-coated 
surface, however twice as many of the CHO-H (FUT1) 
and 3-times more of the CHO-Lea and CHO-Leb were 
bound, consistent with the prolectin staining of the cells 
as analyzed by flow cytometry (Figure 5A). Interestingly, 
after less than 30 mn of binding, the CHO-Lea cells already 
displayed an elongated shape. We thus compared CHO 
and CHO-Lea binding on Lab-tek chamber slides coated 
with either prolectin or poly-lysine. After 2 h, bound 
CHO cells had a round shape regardless of which coating 
was used. CHO-Lea cells were mostly round or ovoid on 
poly-lysine, but most were elongated when bound on the 
prolectin coating (Figure S9).
We next tested the binding of human cancer cell 
lines on the prolectin coating under flow conditions. 
To this end, we injected the cells in a buffer containing 
25 mM of either fucose or galactose. We performed 5 
independent experiments with the prostate cancer cell line 
DU-145, which has good characteristics for this kind of 
experiments, as the trypsinized cells are round and mostly 
well isolated. Despite important variations in the absolute 
number of bound cells, there were always more bound 
cells in presence of galactose, which should not affect 
prolectin, compared to the presence of fucose, which 
blocks prolectin. This pattern was also observed with 
the other cancer cell lines MCF-7, OVCAR-3 and HT-29 
(Figure 5B). The affinity of prolectin galactose is weak but 
not inexistent (see [16]), which means that the efficiency 
of adhesion of those two cell lines to the prolectin 
coating might have been somewhat underestimated in our 
experimental design. We also found that bound cells were 
those expressing the highest level of prolectin ligands 
(Figure S10).
Binding of MCF10A-LXSN and MCF10A-
Kras(v12) cells to a prolectin coating was also compared 
using the BioFlux system. Flow cytometry analysis was 
performed in parallel. As already mentioned, prolectin 
stained MCF10A-LXSN cells more strongly than 
MCF10A-Kras(v12) cells. An even more important 
difference was found when looking at adhesion of cells to 
the prolectin layer under the shear flow conditions, since 
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Figure 4: Prolectin is a human C-type lectin that recognizes similar fucosylated ligands as BC2L-C-Nt and efficiently 
binds to tumor cell lines and tumor tissues. (A) Diagram of Prolectin structure (CRD: carbohydrate recognition domain; TM: 
transmembrane domain; IC: intra-cytoplasmic domain). (B) Glycan binding assay of prolectin and BC2L-C-Nt. Plates coated with a 
series of fucosylated HBGAs conjugated to HSA or PAA were probed with either biotinylated-BC2L-C-Nt followed by Avidin-HRP or 
tetramers of biotin-prolectin CRD bound to streptavidin-HRP. The results shown are the mean and SEM of three independent experiments. 
(C) Flow cytometry staining of tumor cell lines from various origins. Tetramers of biotinylated-prolectin CRD in complex with streptavidin-
PE, pre-incubated in the absence of sugar or with L-fucose, were bound to the indicated cell lines, which were then analyzed by flow 
cytometry. The bar histogram shows the mean fluorescence intensities. Results are representative of at least two experiments. (D) Prolectin 
preferentially stains epithelial cell lines. The epithelial/mesenchymal cell lines pairs MCF10A-LXSN/MCF10A-Kras(v12) and MCF10A-
PuroR/MCF10A-SNAIL were stained with prolectin as described above. Means and SEM of three independent experiments are shown 
(E) Prolectin binding to tumor tissues. Tetramers of biotinylated-prolectin CRD conjugated with streptavidin-HRP were incubated on fixed 
tissue sections from different tumor (T) or adjacent normal (NT) tissues. To control for the involvement of specific glycan binding in the 
prolectin staining, colon tumor sections were stained as above after prolectin tetramers were incubated with Ca2+, EDTA or Ca2++ L-fucose. 
Colon tissues had been fixed in ethanol whereas breast, lung and uterine tissues were from formalin-fixed TMAs. Magnifications of 20× are 
shown (the black bars represent 100 µm).
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only the epithelial MCF10A-LXSN cells, but not their 
Kras(v12) mesenchymal counterparts, were able to adhere 
(Figure 5C). Prolectin recognizes fucosylated ligands, but 
also high mannose glycans [18]. Thus, in order to get better 
insight into which type of sugar ligands were involved, 
we treated cells with glycosylation inhibitors. First, we 
used 2-fluoro-fucose (2F-Fuc), a competitive inhibitor of 
all the cellular fucosyltransferases. The effect of 2F-Fuc 
treatment on the expression of the fucosylated markers 
was controlled using BC2L-C-Nter. The labeling of treated 
cells was nearly completely abolished (Figure S11). 
2F-Fuc treatment markedly decreased prolectin binding to 
MCF10A-LXSN cells while it did not have any effect on 
the lower binding to MCF10A-Kras(v12) cells, strongly 
suggesting that the difference in staining by prolectin 
between the two cell lines is essentially due to the presence 
of fucose residues on MCF10A-LXSN cells. Moreover, 
2F-Fuc treatment suppressed adhesion of MCF10A-LXSN 
cells to the prolectin coating, showing that fucose residues 
are primarily responsible for the binding (Figure 5C). 
To further delineate the respective role of fucose versus 
mannose recognition by prolectin, we also treated the cells 
with kifunensine (KFN), an α-mannosidase I inhibitor 
that blocks maturation of N-glycan chains maturation and 
consequently increases expression of high mannose chains 
at the cell surface. The increase of mannose presentation 
by KFN was controlled by staining with the mannose-
specific lectin BC2L-A (Figure S11). As expected, KFN 
treatment increased prolectin binding on both cell types. 
However, KFN did not change the efficiency of adhesion 
of these cells to the prolectin layer (Figure 5C). This 
result confirmed that fucosylated ligands play a major 
role in prolectin binding to epithelial cells, while mannose 
residues constitute the remaining ligands on mesenchymal 
cells. However, mannose recognition did not appear to 
significantly contribute to adhesion of prolectin, which 
was mainly fucose-dependent. 
Since a coating of the prolectin CRD was able 
to mediate adhesion of cells under flow, we sought to 
determine whether adhesion would also happen in a cell-
cell interaction context with the native protein. For these 
experiments, we used RAT6 rat fibroblasts transduced with 
a retrovirus containing the whole CTLY11 (CLEC17A) 
prolectin cDNA. About half of the RAT6-CTLY11 cells 
were positive for surface prolectin expression whereas no 
prolectin was detected on the cells transduced with the 
empty vector (RAT6-Neo) (Figure 5D). 
A monolayer of DU-145 cells was grown in the 
BioFlux channel and RAT6-Neo or RAT6-CTLY11 cells 
were injected. We compared the speed of movement 
of RAT6-Neo and RAT6-CTLY11 cells by capturing 
short videos and measuring the distance covered by the 
fibroblasts on image sequences corresponding to 1 second. 
We found that prolectin-expressing fibroblasts passed 
through the channel more slowly than the RAT6-Neo 
cells. We then injected RAT6-CTLY11 suspended in a 
buffer containing either galactose or fucose. Cells were 
found to move significantly more slowly in the presence 
of galactose than in the presence of fucose (Figure 5D). 
Similar results were obtained on a monolayer of MCF-7 
cells (Figure S12). Although involvement of other fucose-
specific lectins cannot be formally excluded, these results 
suggest that the presence of prolectin at the cell surface can 
induce rolling onto a layer of tumor cells.
Higher levels of prolectin ligands are associated 
with lymph node metastasis and elevated FUT1/3 
expression correlates with a worse prognosis
Since endogenous prolectin is expressed in lymph 
nodes, it has the possibility to interact with infiltrating 
tumor cells. In this case, it would be expected that the 
tumor cells retained in the lymph node are those that 
express more prolectin ligands. We therefore compared 
staining of paired primary breast tumors and lymph node 
metastasis with prolectin CRD. A score was established 
corresponding to the estimated percentage of labeled tumor 
cells, modulated by a color intensity index. The score was 
found to be significantly higher for the metastatic tissue 
than for the primary tumor tissue (Figure 6A). 
We next wondered whether there could be some 
relationship between levels of FUT1 and/or FUT3 
expression and the disease progression. We used the 
meta analysis tool bc-GenExMiner which compiles 
transcriptomic data from breast cancer studies (http://
bcgenex.centregauducheau.fr/; [24]). Forest prognostic 
analysis was performed on the whole set of patients 
(irrespective of their nodal or estrogen receptor status) 
and the first pejorative event considered was represented 
by any relapse or death (referred to as “any event”). 
High-level expression (i.e. above the median expression 
of the gene) of both FUT1 and FUT3 was correlated to 
a bad prognosis with hazard ratios of 1.12 (P = 0.0243) 
and 1.14 (P = 0.00966) respectively (Figure 6B an 
Figure S13A). No such correlation was found for other 
fucosyltransferases. Similar results were obtained with the 
KM plotter online platform (http://kmplot.com/analysis/
index.php?p=service&cancer=breast; [25]; See Figure S13B)
Collectively, these results suggest that prolectin could 
help implantation of metastasis in the lymph nodes through 
binding of fucosylated ligands on incoming tumor cells.
DISCUSSION
In this study, we have shown that fucosylated 
motifs such as Ley tend to disappear during the course 
of EMT and that this change reflects repression of the 
FUT1 and FUT3 enzymes expression in mesenchymal 
cells. Consistent with this change in glycosylation, we 
found that the bacterial fucose-binding lectin BC2L-C-
Nt differentially stains epithelial and mesenchymal cells. 
This property was not shared by the well-characterized 
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Figure 5: Prolectin acts as a cell adhesion molecule. (A) Expression of fucosylated markers on normal CHO cells or CHO cells 
engineered to express fucosylated antigens tested by flow cytometry. Cells were introduced in the channels of a BioFlux microfluidic 
system coated with prolectin/streptavidin tetramers under a pressure of 0.1 Dyn/cm2. Unbound cells were washed away and pictures of the 
attached cells were taken at 10x magnification with a Leica DMI 6000B microscope. Bound cells were counted on three different segments 
along the channels and the mean cell densities and SEM are represented on the histogram. (B) DU-145 cells were introduced in the channels 
under a pressure of 0.1 Dyn/cm2 and in presence or 25 mM D-galactose or L-fucose. Unbound cells were washed away and pictures of the 
attached cells were taken. Bound cells were counted in the whole channels. The results of five independent experiments are shown. Due 
to the high variation between experiments, the results are shown separately. Similar experiments were performed with the other tumor cell 
lines MCF-7, OVCAR-3 and HT-29. (C) MCF10A-LXSN and MCF10A-Kras(v12) cells were treated with dimethyl sulfoxide (DMSO, 
green), 5 µM kifunensin (orange), or 400 µM 2F-fucose (blue) during four days and stained with prolectin by flow cytometry as described 
above. Control cells and cells treated with the inhibitors were injected into prolectin-coated BioFlux channels. Unbound cells were washed 
away and pictures of the attached cells were taken. Bound cells were counted in the whole channels. (D) Prolectin expression was tested 
on Rat6-Neo and Rat6-CTLY11 fibroblasts by flow cytometry. Percentages of “positive” cells are indicated. Rat6-Neo and Rat6-CTLY11 
or Rat6-CTLY11 in the presence of 25 mM galactose or fucose were injected in BioFlux channels covered with a layer of DU-145 cells 
under a pressure of 0.05 Dyn/cm2. Films of 1 minute (600 pictures) were acquired on a Leica DMI 6000B microscope using the Metamorph 
software. Chronophotographic images, corresponding to 10 pictures segments of the films, were constructed using the FiJi software and 
distances covered by individual cells were measured. Student tests were performed to assess statistical significance.
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fucose-binding lectin UEA-I. In vitro, BC2L-C-Nt binds 
efficiently to H type 1/3, but poorly to H type 2 [13]. 
This means that if type 2 rather than type 1 structures are 
expressed, which seems to be the case in the breast cell 
lines, BC2L-C-Nt will poorly bind in conditions where the 
level of α1, 3/4 fucosylation is low. In contrast, UEA-I 
has a strong preference for H type 2 and will still bind, 
providing the cells have α1, 2 fucosyltransferase activity. 
This probably explains why BC2L-C-Nt display higher 
specificity than UEA-I for epithelial versus mesenchymal 
cells. We propose that BC2L-C-Nt could be a good tool 
to sort out cells with an epithelial phenotype in a mixed 
Figure 6: Associations between prolectin ligand expression, lymph node metastasis and clinical prognosis. (A) The level 
of staining by the prolectin CRD was quantified on the 10 primary tumor/lymph node metastasis pairs from the breast TMA of Figure 4. 
A global score representing the proportion of stained tumor cells corrected by the staining intensity was established. Prolectin staining 
intensity was scored as +, +/++, +/+++ and ++/+++ and percentage of positive tumor cells was adjusted using coefficients of 1, 1.2, 1.5, 
1.5 and 2 respectively. Pictures of two of the pairs are shown as examples. Statistical significance has been determined using a 2-tailed 
Wilcoxon test. (B) Computational analysis of breast cancer patient data were performed using the online platform bc genexminer (http://
bcgenex.centregauducheau.fr). FUT1 and FUT3 expression are grouped into high and low level expression by comparison with the median 
expression of each gene.  Analysis shown was done on all the patients irrespective of their nodal or estrogen receptor status (AE: Any Event; 
HR: Hazard Ratio).
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population. In the past few years, a great deal of effort has 
been put in the development of various systems for sorting 
circulating cancer cells in the bloodstream (see [26] for 
a review). Considering the vast heterogeneity of cancer 
cells, it is essential to target different markers to achieve 
the best sensitivity and specificity. In this context, BC2L-
C-Nt could be used in combination with other antibodies 
or lectins to improve sorting of the epithelial cancer cells 
from blood. BC2L-C-Nt has been recently described as 
a good probe for embryonic stem cells (ES) or induced 
pluripotent stem cells (iPS) identification [27, 28]. 
Interestingly, those types of pluripotent stem cells tend to 
express epithelial markers such as epithelial cell adhesion 
molecule (EPCAM) or E-Cadherin, which is in contrast 
with the so-called cancer stem cells that are associated 
with a mesenchymal phenotype [29]. It is thus possible 
that BC2L-C-Nt could be used to distinguish between 
different types of stem cells. 
We observed that both FUT1 and FUT3 were down-
regulated in the course of EMT. Potential binding sites for 
SNAIL and ZEB transcription factors are present in the 
FUT1 and FUT3 promoters similar to those contained in 
the E-cadherin promoter, which is known to be repressed by 
proteins from these families [22, 23, 30, 31]. FUT3 seemed 
to be more sensitive to the EMT-related repression as it was 
drastically down-regulated both by expression of Kras(v12) 
and of SNAIL, whereas FUT1 was much more sensitive to 
SNAIL than to Kras(v12). TGF-ß treatment also decreased 
FUT3 expression but not that of FUT1. Very recent data 
show that Kras induces EMT in breast cells via SLUG 
(SNAI2) rather than SNAIL (SNAI1) or ZEB [32], which 
might explain the difference for FUT1 repression between 
MCF10A-Kras or MCF10A cells treated with TGF-ß on the 
one hand, and MCF10A-SNAIL on the other hand. 
TGF-ß treatment was poorly efficient at inducing 
EMT in our hands. Using MCF10A cells, Zhang et al have 
shown that TGF-ß-induced EMT is a two-step process, 
going through a SNAIL-driven intermediary stage before 
reaching the complete mesenchymal state [33]. For 
reasons difficult to explain, we could only achieve a partial 
transition. However, we think our results with cancer cell 
lines and with the two MCF10A-based EMT models 
clearly demonstrate that fucosylation is down regulated in 
breast mesenchymal cells.
 Interestingly, Sakuma et al. have shown in colon 
cancer cells that following induction of EMT by EGF, 
FUT2 expression is repressed via down-regulation of the 
colon-specific transcription factor CDX-2. However, in 
contrast to our results, the level of FUT3 expression was 
up-regulated rather than down-regulated due to increased 
recruitment of c-Myc to the FUT3 promoter [34]. It is 
possible that in the context of colon cells, a higher level 
of activating signals makes it possible to bypass the EMT-
driven repression of FUT3. In a very recent study, Tan 
et al. have used a murine mammary cell line (NMuMG) 
with or without TGF-ß treatment to extensively analyze 
the glycosylation changes occurring during EMT. In a 
lectin microarray, they found reduced staining by the Fuc 
(α1, 3)-specific lectin from Lotus tetragonolobus on the 
TGF-ß treated cells. Transcriptome analysis also showed 
reduced expression of several FUTs [35]. 
Mesenchymal cells have a higher invasive potential 
than epithelial ones. Cancer cells invasiveness is often linked 
to increased expression of selectin ligands (SLex and SLea) 
that allow extravasation and foreign tissues colonization 
[36–40]. It has been shown that increased expression of 
FUT1 in HT-29/M3 increases α2-fucosylation of the type 
2 (Galß1-4GlcNAc-R) disaccharide which, by competing 
with sialylation, leads to a decrease of the synthesis of 
SLex and hence of the invasive and metastatic capacities 
of the cells [41]. In the study of Sakuma et al. [34], EMT-
associated down-regulation of FUT2 and induction of FUT3 
expression leads to increased levels of SLex on the cell 
surface. Thus, it seems contradictory that in breast cancer 
cell lines, induction of EMT leads to repression of FUT3 
expression and suppression of both neutral and sialylated 
Lewis antigens presentation. As SLex was detected on 
mesenchymal cells such as BT-549, MCF10A-KRAS or 
MCF10A-SNAIL with the KM-93 antibody only but not 
with the HECA-452 antibody, it is likely that this is due to 
the cross-reactivity of KM-93 with sialylated lactosamine 
[17], suggesting that the decrease of FUT3 expression 
also leads to a decrease of SLex presentation. Previous 
reports have indeed suggested that expression of SLex 
and E-Selectin ligands was dependant on FUT3/FUT6 
expression in breast tumors and cell lines [3, 42]. 
Functional significance of Ley overexpression 
by epithelial cancer cell is less well understood. Hotta 
et al. reported that Ley was deleted in the invasive front 
of oral squamous tumors and that expression of FUT1 
and Ley in squamous cancer cell lines is associated with 
reduced proliferation and invasiveness [43]. However, 
in oral cancers, Ley has also been suggested to promote 
cell migration via stabilization of EGFR and downstream 
signaling [44]. Interestingly, a recent study shows that 
overexpression of FUT1 in bladder cancer cell lines 
increases integrin ß1 activity and enhances cell adhesion 
[45]. Further studies are needed to better understand the 
regulation and functional consequences of glycosylation 
changes during EMT. 
We also showed that the C-type lectin prolectin, 
expressed in lymph nodes, was a fucose-dependent 
epithelial cell adhesion molecule. Prolectin also reacts 
with polymannosylated ligands and therefore does not 
distinguish between epithelial and mesenchymal cells 
as well as BC2L-C-Nt when used as a probe for flow 
cytometry. Nevertheless, we showed that fucosylated 
cells could adhere to a layer of prolectin in low flow 
conditions. Mesenchymal or “de-fucosylated” epithelial 
cells show dramatically reduced adhesion to prolectin. 
Rat fibroblasts stably expressing Prolectin also showed 
reduced velocities when placed under flow on a tumor 
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cell monolayer. We could not observe actual adhesion 
of the prolectin-expressing cells on tumor cells in those 
conditions. It might be argued that rat fibroblasts are not 
the most appropriate model to study cell-cell adhesion to 
human tumor cells. It is also possible that the density of 
prolectin at the fibroblast surface is not sufficient to allow 
firm adhesion such as what occurs on the surface coated 
with prolectin CRD. It would be interesting in the future 
to obtain a B-cell line with or without prolectin to perform 
the fluidic experiments in more physiological conditions. 
In addition, as prolectin has a cytoplasmic tail containing 
SH2 and SH3 domains [16], it would be interesting to 
determine if interaction of prolectin expressing B-cells 
with tumor cells triggers some signaling pathways in 
the B-cells and the consequences that such signaling 
could have in terms of B-cell activation and functional 
properties. 
Although the exact role of prolectin interaction with 
tumor cells is not clear yet, we provide indirect evidence 
that it could be involved in metastasis implantation in 
lymph nodes. Firstly, meta-analysis of breast cancer data 
shows that high levels of expression of FUT1 and FUT3 
are associated with a bad prognosis. A higher expression 
of genes coding those fucosyltransferases can lead to a 
higher presentation of fucosylated ligands for prolectin 
at the tumor cell surface. Secondly, when probing with 
the prolectin CRD, we observed more intense staining 
of lymph node metastasis than of the matching primary 
tumors, suggesting that tumor cells that have a greater 
ability to interact with prolectin, might initiate metastasis 
development more efficiently in the lymph nodes. It has 
to be noticed that the role of tumor cell interaction with 
prolectin-expressing cells will be difficult to directly test 
in vivo, since rodents do not possess an ortholog for the 
CLEC17A gene.
We propose the model illustrated in Figure 7. In a 
carcinoma overexpressing fucosylated motifs such as Ley 
and SLex, some cells will go through an EMT, allowing 
them to detach from their original tissue and migrate to 
blood or lymphatic vessels. During EMT, Ley and SLex 
Figure 7: Proposed model for the roles of prolectin and fucosylated antigens in lymph node metastasis. Increased 
expression of both neutral fucosylated glycan motifs such as Ley and charged fucosylated structures such SLea/x is observed on primary 
tumor cells as compared to their normal counterpart. These fucosylated markers, are lost during EMT that allows tumor cells to migrate and 
pass into the blood or lymphatic streams. When reaching the target lymph node, these cells use the selectin ligands for extravasation and 
undergo MET. The latter step will be accompanied by re-expression of fucosylated ligands through FUT1 and FUT3 expression, thereby 
allowing binding to prolectin that will contribute to the settlement of the metastatic cells in the lymph node.
Oncotarget14www.impactjournals.com/oncotarget
disappear from the cell surface. By a process of MET, 
tumor cells will re-express fucoslylated ligands. The SLex 
motifs allow cancer cells to interact with the endothelium 
of the lymph node afferent vessels and to exit from the 
blood/lymph stream. Upon entrance into the lymph node, 
neutral fucosylated ligands allow carcinoma cells to 
interact with germinal center B cells expressing prolectin, 
which will help them to settle in the lymph node.
Reticker-Flynn and Bhatia have just described a 
somewhat similar involvement of a lectin-carbohydrate 
interaction in the establishment of the metastatic niche. 
In their case, overexpression of the Thomsen-Friedenreich 
antigen (Galß1-3GalNAc) by lung adenocarcinoma 
metastatic cells allowed them to interact with galectin-3 
expressed on pro-tumorigenic leucocytes [46].
Interestingly, during the preparation of this 
manuscript, two studies have challenged the idea that EMT 
would be required for metastasis [47, 48]. This means that 
epithelial cancer cells could actually leave the primary 
tumor, migrate to the lymph node and interact with prolectin 
without the need of going through EMT/MET cycles.
In conclusion, our study provides a direct link 
between the mesenchymal state and repression of some 
fucosyltransferases expression. We also describe the 
bacterial lectin BC2L-C-Nt as a new tool to monitor EMT 
and the human C-type lectin prolectin as a potential new 
player in lymph node metastasis.
MATERIALS AND METHODS
Cell culture
MCF-7, T47-D, BT-549, DU-145 and OVCAR3 
cells (obtained from ATCC) were grown in RPMI 1640 
GIBCO (Life Technologies) supplemented with 10% 
Fetal Calf Serum (FCS) GIBCO. The CHO cell lines 
were grown in RPMI-10% FCS supplemented with 
10 µg/ml each of adenosine, thymidine and 2-deoxy-
adenosine (Sigma). CHO-H cells were obtained by stable 
transfection of CHO cells with the rabbit FUT1 enzyme 
as described in [49]. CHO-Lea and CHO-Leb were a kind 
gift from Jan Holgersson [50]. CAL-51 (obtained from 
DSZM), MDA-MB-231, ZR-75.1, HT-29 (obtained from 
ATCC), RAT6-Neo and RAT6-CTLY11 were grown in 
DMEM containing 4,5 g/l glucose and supplemented 
with 5% (CAL51, MDA-MB-231) or 10% FCS. 100 µg/
ml of G418 (neomycin) at 100 µg/ml was added to the 
RAT6 fibroblasts medium to maintain prolectin expression 
[16]. MCF10A-Kras(v12) and the empty vector control 
MCF10A-LXSN are a kind gift from Dr Ben Ho Park [51]. 
MCF10A-SNAIL cells and their corresponding MCF10A-
PuroR controls were obtained from Dr Stéphane Ansieau 
[52]. MCF10A cell lines were grown in DMEM:HamF12 
(1:1) GIBCO supplemented with 5% Horse Serum 
GIBCO, 0,5 µg/ml hydrocortisone (Sigma), 20 ng/ml 
human epidermal growth factor (Life Technologies), 10 µg/
ml bovine insulin (Sigma), 100 ng/ml Toxin from Vibrio 
cholerae (Sigma) and 50 mM HEPES GIBCO. All culture 
media were supplemented with 2 mM L-glutamine GIBCO 
and 1% penicillin-streptomycin GIBCO®. For MC10A-
SNAIL and their MCF10A-PuroR counterpart, 0.5 µg/ml 
of Puromycin was also added to maintain the plasmid.
Cells were grown at 37°C with 5% CO2.
Treatment with TGFβ1 and TGFβ signaling 
inhibitor
To induce EMT, cells were treated with 5–10 ng/ ml 
of TGF-ß1 (e-Bioscience or R & D). Cells were passaged 
continuously under TGF treatment or treated during 
4 days, changing the medium every two days. In some 
experiments, cells were treated with 0,5 µM of the 
TGFßRI inhibitor A83-01 (Sigma Aldrich) to maintain the 
epithelial phenotype (control cells) or to improve the MET 
process after TGF-ß withdrawal.
Antibodies and lectins
We used the following antibodies to detect 
glycoantigens: anti-Lea (7-LE; 1/100); anti-Leb (LM- 137; 
1/10), anti-Lex (3E1; 1/10; EFS Nantes), anti-Ley 
(12- 4LE; 1/400), anti-H type 3 (Mbr1; 5 µg/ml; Enzo life 
Science), anti-SLex (KM-93; 10 µg/ml; Merck-Millipore, 
Notthingham, U.K and HECA-452; 250 µg/ml; BD 
Bioscience) and anti-SLea (19-9; 1/200). 7-LE, LM-137, 
12-4LE and 19-9 antibodies were from J. Bara (Villejuif) 
and U892 (Nantes). All the above antibodies are mouse 
monoclonal antibodies except from HECA-452, which was 
produced in rat. E-Cadherin was detected with 24E10 rabbit 
monoclonal antibody (1/200; Cell Signaling Technology) 
and vimentin with IF01 mouse monoclonal antibody (1/20 
for flow cytometry and 1/50 for immunofluorescence; 
Calbiochem, Merck Millipore). Prolectin was detected with 
a rabbit polyclonal antibody [16].
We also used several recombinant bacterial lectins 
(BC2L-A, BC2L-C-Nt, PA-IL, RSL) produced in E. Coli 
in the CERMAV laboratory (CNRS UPR5301, Grenoble, 
France) as well as the plant lectin UEA-I (Vector 
laboratories, Burlingame, CA).
Plasmid construction
For expression of the CRD from prolectin, a pET-
24a-Pro vector was obtained by gene synthesis from 
GENEART (Life Technologies; Regensburg, Germany). 
This plasmid drives expression of the CRD of prolectin 
(residues 247 to 380) with the biotinylation acceptor 
sequence GLNDIFGAQKIEWHE appended at the 
C-terminus, as described in [16].
Preparation of biotinylated prolectin tetramers
A 3 Liters culture of E.Coli strain BL21(D3) 
transformed with the pET-24a-Pro plasmid was prepared 
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and prolectin expression was induced by addition of 
1 mM Isopropyl ß-D-1 thiogalactopyranoside (IPTG). 
After incubation for 5 h at 37°C, bacteria were pelleted 
and resuspended in saccharose buffer before freezing. 
Bacteria were thawed, sonicated and digested with 
300 µg/ml Lyzosyme. Inclusion bodies were washed 8 
times with wash buffer (50 mM Tris-HCl pH 8, 100 mM 
NaCl, 0.5% Triton X-100 + protease inhibitors without 
EDTA (Roche)), resuspended in 8 M urea for protein 
denaturation, collected by ultracentrifugation and protein 
concentration was determined. Inclusion bodies (8– 16 mg) 
were resuspended in 125 ml of renaturation buffer 
(100 mM Tris-HCl pH 8, 25 mM CaCl2, 0.5 M NDSB256 
(Sigma), 5 mM reduced glutathione, 0.5 mM oxydized 
glutathione + protease inhibitors without EDTA (Roche)) 
and incubated for 3 days at 4°C under slow agitation. The 
renatured protein was concentrated on filters with 1-3 kDa 
cut-off (Amicon) and biotinylated by incubation with the 
BirA enzyme for 5 h. The biotinylated protein was applied 
on a HiLoad S200 gel filtration column (GE Healthcare). 
Elution was performed in phosphate buffer saline (PBS) 
and fractions corresponding to the monomer of prolectin 
were pooled, aliquoted and stored at −80°C.
Since lectins affinity for glycosylated ligands is 
generally improved when they are in multimeric states, 
we formed tetramers of prolectin by taking advantage 
of the property of the streptavidin molecule to have 4 
biotin-binding sites. Biotinylated-prolectin monomers 
were incubated with streptavidin-horseradish peroxidase 
(strepatvidin-HRP; Vector laboratories, Burlingame, 
CA) or streptavidin-phycoerythrin (streptavidin-PE; BD 
Pharmingen) at a molar ratio of 1:5 in TBS-BSA, 10 mM 
CaCl2 for 1–2 h at room temperature. Tris-buffered saline 
(TBS) was used instead of PBS to avoid the formation of 
calcium phosphate precipitates. These tetramers were then 
used in the different assays described below.
Enzyme linked lectin assay
Oligosaccharides conjugated to polyacrylamide beads 
(PAA) were obtained from N. Bovin (Shemyakin Institute 
of Bioorganic Chemistry, Moscow, Russia). Human serum 
albumin (HSA) conjugated with oligosaccharides were 
purchased from Isosep (Tullinge, Sweden). Detailed 
formulas of the oligosaccharides are given in Table S3.
Synthetic oligosaccharides were used at 0.1 mg/ml. 
All samples were diluted in coating buffer (Carbonate-
Bicarbonate 0.1 M pH 9.5) and adsorbed in duplicates 
on “Maxisorb” 96 well- plates (Nunc, ThermoFisher 
Scientific, Waltman, MA) with overnight incubation at 
37°C. After 3 washes with PBS-0.05% Tween20 (PBS-T), 
blocking of the non-specific protein binding sites was 
performed with PBS-5% BSA for 1 h at 37°C. Biotinylated 
BC2L-C-Nt diluted to 1 µg/ml in TBS-1% BSA, 10 mM 
CaCl2 was added to the plate for 2 h at room temperature. 
After 3 washes with PBS-T, streptavidin-HRP at 5 µg/ml 
in PBS-1% BSA (in the wells incubated with BC2L-C- Nt) 
or 4 µg/ml of prolectin tetramerized with streptavidin-
HRP in TBS-1% BSA, 10 mM CaCl2 (see above) were 
added to the plate, followed by 2 h incubation at room 
temperature. After 3 washes with PBS-T, plates were 
developed by adding 200 µl/well of OptEIA substrate 
(3, 3′, 5, 5′ tetramethylbenzidine, BD). The reaction was 
stopped by adding 50 µl/well of 1 M phosphoric acid and 
optical density was read on a iMark Microplate Reader 
(Bio-Rad). 
Flow cytometry
Cells were trypsinized, aliquoted and resuspended 
in PBS-0.1% BSA (PBS-BSA). After 1–2 h incubation 
at 4°C with biotinylated lectins diluted in PBS-BSA, 
cells were washed 3 times with PBS-BSA and incubated 
with streptavidin-PE (BD Pharmingen) for 30 mn at 4°C. 
Alternatively cells were incubated directly with 10 µg/ml 
prolectin in complex with streptavidin-PE in TBS-0.1% 
BSA, 10 mM CaCl2 (or 2.5 mM EDTA for the negative 
control) for 1–2 h at 4°C. 
For detection of the glycosylated antigens, cells 
were incubated with primary antibodies diluted in 
PBS-BSA for at least 30 mn at 4°C. After washes with 
PBS-BSA, the cells were incubated with Goat F(ab’)2 
anti- mouse IgG (H + L)-FITC (Beckman) or Goat anti-rat 
IgG (H + L)-FITC (Novex, Life Technologies) 1/200 in 
PBS-BSA for 30 mn at 4°C. 
In all cases, cells were washed 3 times with PBS, 
resuspended in PBS and analyzed on a FACSCalibur flow 
cytometer (BD).
Immunofluorescence
Cells were fixed with paraformaldehyde 4% in 
PBS for 20 mn at room temperature. Blocking and 
permeabilization were then performed simultaneously 
using PBS-0.1% Triton X-100-10% FCS. Cells were 
incubated sequentially with anti-E-Cadherin and anti-
Vimentin (see above) diluted in PBS-10% FCS for 1 h 
at room temperature. After washes with PBS-10% FCS, 
cells were incubated with Goat anti-rabbit IgG (H + L)-
DyLight 488 (KPL), 1/400 and then with Goat anti-mouse 
IgG (H + L)-Rhodamin (Chemicon, Merck Millipore), 
1/200 and NucBlue Live Stain (Molecular Probes, Life 
Technologies). After washes with PBS, slides were 
mounted in ProLong Gold anti-fade reagent (Molecular 
Probes, Life Technologies).
Tissue sections 
Ethanol-fixed colorectal tumor sections were 
obtained after cancer surgery. They were collected before 
the French law 88-138 of December 20, 1988 concerning 
resection of human tissues after death for scientific 
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investigations. The samples were obtained from the Nantes 
University Hospital Center for Biological Resources 
(http://relib.fr), under the Cancerology program approved 
by the ministry of research (approval DC-2011-1399). A 
breast tumor tissue microarray (TMA; formalin-fixed; 40 
tumors, 10 paired lymph node metastasis and 10 paired 
adjacent “normal” tissue), a lung tumor TMA (formalin-
fixed; 40 tumors, 7 paired lymph node metastasis, 2 
paired bone metastasis, 1 paired soft tissue metastasis and 
10 paired adjacent “normal” tissue) as well as a uterine 
cervix tumor TMA (formalin-fixed; 40 tumors, 5 paired 
lymph node metastasis and 5 paired adjacent “normal” 
tissue) were bought from SuperBiochips Laboratories 
Ltd (Seoul, South Korea). The company certifies that the 
“human material has been removed or collected with the 
donor’s prior consent and that no payment whatsoever has 
been made to the latter”.
Histochemistry
The tissue sections were deparaffinized, then 
endogenous peroxidases were blocked by 20 min incubation 
in PBS-0.3% Hydrogen peroxide. Non-specific binding 
was blocked by 60 min incubation in PBS-5% BSA. 
Prolectin-Streptavidin HRP tetramers in TBS-1% BSA-
10 mM CaCl2 were added for 2 h at room temperature. 
After 3 washes with PBS, peroxidase substrate (AEC kit, 
Vector Laboratories) was added to the slide for 10–20 
min followed by quick soaking in Mayer’s hematoxyllin 
solution (Vector Laboratories) for contrast staining.
Slides were imaged with a Nanozoomer slide 
scanner (Hamamatsu, Hamamatsu City, Japan).
Adhesion assay under flow
Microfluidic experiments were performed using the 
BioFlux system (Fluxion) in a 48-well plate format.
BioFlux® microchannels were coated with tetramers 
of prolectin-streptavidin (100 µg/ml) in coating buffer 
(carbonate-bicarbonate 0.1 M pH 9.5) containing 0.5 mM 
CaCl2, overnight at 37°C. Cells were trypsinized, counted 
and resuspended at 5 × 106 cells/ml in PBS containing 
Ca2+ and Mg2+ and 5% FCS.  25 mM of D (+)-Galactose 
(Sigma) or L-(−)-Fucose (Sigma) were added at final 
concentrations of 25 mM as indicated in Figure legends. 
The cell suspension was loaded in the entry well of the 
BioFlux plate and a shear flow of 0.05-0.1 Dyn/cm2 was 
applied by the BioFlux pump, to inject the cells into the 
microchannel. A Series of 600 pictures, corresponding to 
60-second films were recorded with a Leica DMI 6000B 
microscope. After the video acquisition, microchannels 
were washed 10 min with PBS containing Ca2+, Mg2+ at 
4 Dyn/cm2 in order to remove unbound cells and pictures 
of the cells attached along the whole channels were taken.
In some cases cells were detached by flushing with 
PBS-0.02% EDTA and trypsin and stained with prolectin 
for fluorescence or flow cytometry analysis. Video data 
were analyzed by chronophotography on 10 pictures 
segments, using the Fiji software (http://fiji.sc).
qRT-PCR
RNA extractions were performed using the 
Nucleospin RNA II purification kit (Macherey Nagel) 
following instructions of the manufacturer. RNA 
concentration was measured using a Nanodrop (Thermo 
Fisher Scientific) instrument. Reverse transcription was 
performed on 0.5-1 µg of total RNA with oligo-dT and 
the Superscript II reverse transcriptase (Life Technologies) 
as recommended by the manufacturer with 1-2 µl of the 
cDNAs used for the qPCR step.
For FUT1 and FUT3, the Taqman Universal PCR 
Mastermix (Applied Biosystems, Life Technologies) was 
used with the primers and probes described by Nyström et 
al ([53], See Table S1). GAPDH was used for normalization 
using Taqman Pre-developped Assay Reagents primers and 
probe mix (Applied Biosystems, Life Technologies). For 
CDH1 and B­Actin, qPCR was performed using the Brilliant 
II SyBrGreen Mastermix (Agilent) and primers indicated in 
Table S2. qPCRs reactions were ran on a Mx3500P qPCR 
machine (Agilent). For normalization of the qPCR results, 
the ΔΔCT method was applied.
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Supplementary Materials
Supplementary Figure S1: Biosynthetic pathway of the histo-blood group antigens. α1, 2 fucosyltransferases (FUT), 
α1-3/4 FUT and α2-3 sialyltransferases (ST3Gal) mainly responsible for synthesis of the various intermediates are indicated. N-acetyl 
galactosamine or galactose moieties can be added to the terminal galactose to make the A or B antigens respectively.

Supplementary Figure S2: Lectin binding on breast cell lines. The indicated breast cell lines have been stained with recombinant 
biotinylated lectins followed by streptavidin-PE and analysed by flow cytometry. Mean fluorescence intensities are presented. The results 
are representative of at least two experiments.
Supplementary Figure S3: Expression of fucosylated antigens by MCF10A cells treated with TGF-β. MCF10A-LXSN 
epithelial cells were treated with either 0,5 μM A83-01 (MCF10A-LXSN) or 5 ng/ml TGF-β R&D (MCF10A-TGF) during four days. 
TGF-β was then withdrawn and cells were grown four more days in presence of 0,5 μM A83-01 (MCF10A-MET). Cells were analyzed by 
flow cytometry as described in Figure l.
Supplementary Figure S4: Fucosyltransferases genes expression in breast cell lines. Expression levels of the FUTα1-2 
(FUT1 and 2) and FUTα1-3/4 (FUT3, 4, 5, 6, 7 and 9) genes were extracted from a transcriptomic dataset of 51 breast cancer cell lines 
available in the NCBI database (GEO n° GSE12777) thanks to the online analysis tool BioGPS (http://www.biogps.org) and cell lines were 
sorted according to their overall gene profile subtypes (according to the classification of Neve RM et al, Cancer Cell 2006 and Kao J et al 
PlosOne 2009). Mean expression level for each FUT gene and standard deviations are shown.
Supplementary Figure S5: Fucosyltransferases genes expression in MCF10A-PuroR/MCF10A-SNAIL. Total RNAs were 
extracted from the different cell lines, cDNAs were then synthesized using oligo-dT and subjected to qPCR analysis with FUT1, FUT3 and 
GAPDH specific primers and probes. FUT1 and FUT3 expression levels are presented relatively to GAPDH expression. Data shown are 
representative of three independent experiments.

Supplementary Figure S6: FUT1 and FUT3 promoters contain binding sites for EMT-inducing transcription factors.
(A) Sequences of FUT1 and FUT3 promoters. The E2-boxes CACCTG or CAGGTG that are binding sites for SNAIL are underlined. 
Moreover, bipartite elements (C)AGGTG/CACCT(G) (in red) are binding motifs for ZEB1/2. (B) Expression of FUT1 and FUT3 varies 
inversely with that of ZEB1/2. Data of the 51 breast cancer cell lines transcriptome were analysed as described above. (Basal Unk.: Basal 
cell lines for which the A or B classification is unknown, SNAI1 = SNAIL; SNAI2 = SLUG).
Supplementary Figure S7: Staining by prolectin of leucocyte populations infiltrated in tumors. Tetramers of biot-prolectin 
CRD/streptavidin-HRP were bound to a paraffin embedded TMA from lung cancer. An example of tumor is shown with infiltrating 
leucocytes strongly stained by prolectin as well lymphoid tissue from the same patient. 20x magnifications are shown with inlets at 40x 
magnfication. (T = Tumor).
Supplementary Figure S8: Phenotyping of the CHO, CHO-H, CHO-Lea and CHO-Leb. The CHO cell lines were analysed 
by flow cytometry with the antibodies 7LE (anti-Lea) and LM137 (anti-H type 1/Leb) followed by anti-mouse-FITC and the biotinylated 
lectin UEA-I (α2-Fucose specific) followed by streptavidin-PE.
Supplementary Figure S9: Comparison of CHO-Lea binding to poly-lysine and a prolectin coating. Lab-tek chamber 
slides have been coated with prolectin/strepatvidin tetramers or poly-L lysine. CHO and CHO-Lea cells were bound for 2 hours. After 
careful and thorough washes, the cells were stained with Hoechst (nuclei) and phalloïdin (actin). Pictures were taken at ×63 magnification 
with a Zeiss Axiovert 200 microscope.
Supplementary Figure S10: The cells that bind to prolectin under shear flow conditions are those having the highest 
expression of prolectin ligands. DU-145 were injected into Prolectin-coated BioFlux channels. Unbound cells were washed away with 
PBS (Ca,Mg) and collected in the output well. Bound cells were detached by trypsin treatment. Both bound and unbound cells were stained 
with Prolectin/Strep-PE tetramers and analyzed with the Amnis Image Stream X II flow cytometer.
Supplementary Figure S11: Inhibition of fucosylation by 2F- Fuc treatment and increase of mannosylation by KFN 
treatment on MCF10A cells. MCF10A-LXSN and MCF10A-Kras(v12) were treated with DMSO (green), 5 μM kifunensin (orange) 
or 400 μM 2 fluoro-fucose (blue) during four days. Cells were then harvested, probed with BC2L-C-Nt-biot (to stain fucosylated structures) 
or BC2L-A-biot (to stain high mannose structures) followed by streptavidin-PE and analyzed on FACSCalibur flow cytometer.
Supplementary Figure S12: Interaction of MCF- 7 cells with prolectin- expressing fibroblasts. Rat6-Neo and Rat6-CTLY11 
or Rat6-CTLY11 in presence of 25 mM galactose or fucose were injected in BioFlux channels covered with a layer of MCF-7 cells under 
a pressure of 0,05 Dyn/cm2. Films of 1 minute (600 pictures) were acquired on a Leica DMI 6000B microscope using the Metamorph 
software. Chronophotographic images, corresponding to 10 pictures segments of the films, were constructed using the FiJi software and 
distances covered by individual cells were measured. Student t-tests were performed to assess statistical significance.

Supplementary Figure S13: Prognostic value of FUT1 and FUT3 in breast cancer. (A) Computational analysis of breast cancer 
patients data were performed using the online platform bc genexminer (http://bcgenex.centregauducheau.fr). FUT1 and FUT3 expression 
are grouped into high and low level expression by comparison with the median expression of each gene. Analysis shown was done on all 
the patients irrespective of their nodal or estrogen receptor status. (B) Computational analysis was also performed using the online platform 
KM plotter (http:/ /kmplot.com/ analysis/index.php?p=service&cancer=breast) using the Jetset best probe set and automatic selection of the 
best cutoff to split patients. Analyses are shown on all patients and the time represents distant metastasis free survival.
Supplementary Table S1: Lectins
Lectin Species Specficity Main Ligands Working concentration
PA-IL Pseudomonas aeruginosa Gal Gb3 20 μg/ml
RSL Ralstonia solanacearum Fuc Blood group antigens 0,1 μg/m
BC2L-A Burkholderia cenocepacia Man Dimannoside 2 μg/ml
BC2L-C-Nt Burkholderia cenocepacia Fuc H type 1/3, Lewis Y 5–10 μg/ml
UEA-I Ulex europeaus Fuc (α 1, 2) H type 2 1 μg/ml
Supplementary Table S2: Primers and probes used for qRT-PCR analysis
Gene Acces. nb Forward primer Reverse primer Probe
FUT1 NM_000148 AGGTATAAACACAC 
CCTCTGTGCTT
GAGTTCAGGGACAG 
ACAGT GGTT
AAACTGGCAGGTACCGT 
GCTCATTGC
FUT3 NM_000149 GGGATCCCTTTTCG 
TCACACT
CGAACTGGTCTAAG 
CCTTGCA
AGGTGACCTACAGGCTC 
CGCTCGA
CDH1 NM_004360.3 GGGCGAGTGCCAA 
CTGGACC
CCAGCGGCCCCTTC 
ACAGTC
/
SNAI1 AF155233.1 GACCCCAGTGCCTC 
GACCACTA
CAGCAGGTGGGCCT 
GGTCGTA
/
SNAI2 NM_003068.4 GACCCGCTGGCAA 
GATGCCG
GCTGGGCGTGGAAT 
GGAGCA
/
b-Actin X00351.1 AGAAAATCTGGCAC 
CACACC
CAGAGGCGTACAGG 
GATAGC
/
Supplementary Table S3: Synthetic oligosaccharides used for the ELISA
Poly-
Acrylamide 
(PAA)
A type 2 GalNAcα3[Fucα2]Galβ4GlcNAcβ-R1
A tri GalNAcα3[Fucα2]Galβ-R1
A di GalNAcα3Galβ-R1
B type 2 Galα3[Fucα2]Galβ4GlcNAcβ-R1
B tri Galα3[Fucα2]Galβ-R1
B Di Galα3Galβ-R1
H Di [Fucα2]Galβ-R1
H type 2 [Fucα2]Galβ4GlcNAcβ-R1
H type 3 [Fucα2]Galβ3GalNAcα-R1
Lea Galβ3[Fucα4]GlcNAcβ-R1
Leb [Fucα2]Galβ3[Fucα4]GlcNAcβ-R1
Lex Galβ4[Fucα3]GlcNAcβ-R1
Ley [Fucα2]Galβ4[Fucα3]GlcNAcβ-R1
Human serum
albumine (HSA)
A tri GalNAcα3[Fucα2]Galβ-R2
A hepta GalNAcα3[Fucα2]Galβ3[Fucα4]GlcNAcβ3Galβ4Glcβ-R2
B tri Galα3[Fucα2]Galβ-R2
H type 1 [Fucα2]Galβ3GlcNAcβ-R2
H type 2 [Fucα2]Galβ4GlcNAcβ-R2
Lea Galβ3[Fucα4]GlcNAcβ-R2
Leb [Fucα2]Galβ3[Fucα4]GlcNAcβ-R2
Lex Galβ4[Fucα3]GlcNAcβ-R2
Ley [Fucα2]Galβ4[Fucα3]GlcNAcβ-R2
Supplementary Table S4: Surface expression of Lex and Ley on the tumor cell lines used for the 
prolectin binding experiments
Cell lines Lex (3E1) Ley (12–4Le)
MCF-7 + + + +++
HT-29 + + + +
OVCAR-3 +++ +++
DU-145 ++ +/−
